More specifically, throughout the Class Period, Edwards Lifesciences repeatedly assured investors that its TAVR platform was positioned for "strong sustainable growth" well into the future ...

Edwards Lifesciences has long been a dominant player in the TAVR market, but recent data suggests a moderation in growth. The company has revised its 2024 worldwide TAVR outlook to 5-7% year-over ...

On Friday, TD Cowen reaffirmed its Hold rating on shares of Edwards Lifesciences (NYSE:EW) with a steady price target of $70.00. The firm's outlook was influenced by anticipated favorable outcomes ...

Specifically, Edwards' claims and confidence relied far too heavily on their perceived ability to engage the claimed low-treatment-rate population of patients and an overestimation of the desire for ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Edwards' expected revenue for the fiscal year 2024, particularly as it related to the ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical device company specializing in heart valves and hemodynamic monitoring, is navigating a challenging landscape in the cardiovascular market ...

One of Edward Lifesciences’ core products is Transcatheter Aortic Valve Replacement (“TAVR”). The Edwards Lifesciences class action lawsuit alleges that defendants throughout the Class ...

On Friday, TD Cowen reaffirmed its Hold rating on shares of Edwards Lifesciences (NYSE:EW) with a steady price target of $70.00. The firm's outlook was influenced by anticipated favorable outcomes ...

Edwards Lifesciences, a holding within our global and US portfolios, is a global leader in both surgical heart valves and transcatheter aortic valve replacement (TAVR). By expanding access to ...

The Company attributed the TAVR setback to the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” On this news, Edwards Lifesciences ...